|
SMAD5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.29890020750656E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.07900005491746E-09 |
| Normal-vs-Stage2 |
4.763700E-02 |
| Normal-vs-Stage3 |
7.98550003899834E-10 |
| Normal-vs-Stage4 |
8.68510041662773E-10 |
| Stage1-vs-Stage2 |
6.689700E-02 |
| Stage1-vs-Stage3 |
1.076570E-01 |
| Stage1-vs-Stage4 |
2.285700E-02 |
| Stage2-vs-Stage3 |
1.185960E-02 |
| Stage2-vs-Stage4 |
2.380300E-03 |
| Stage3-vs-Stage4 |
3.298800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.02470032459223E-10 |
| Normal-vs-AfricanAmerican |
1.355140E-03 |
| Normal-vs-Asian |
7.71279999978169E-07 |
| Caucasian-vs-AfricanAmerican |
4.856000E-01 |
| Caucasian-vs-Asian |
9.259800E-01 |
| AfricanAmerican-vs-Asian |
5.359400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.29180000036011E-07 |
| Normal-vs-Female |
5.61670043808249E-10 |
| Male-vs-Female |
9.176800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.84479999451892E-08 |
| Normal-vs-Age(41-60Yrs) |
8.13520000253476E-08 |
| Normal-vs-Age(61-80Yrs) |
1.1503999974849E-08 |
| Normal-vs-Age(81-100Yrs) |
1.330450E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.852200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.739800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.584200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.045800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.160800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.812600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.819200E-04 |
| Classical-VS-Follicular |
8.234500E-02 |
| Classical-VS-Other |
4.805000E-01 |
| Classical-VS-Normal |
5.93399995807431E-09 |
| Tall-VS-Follicular |
6.04699999999792E-05 |
| Tall-VS-Other |
3.776600E-01 |
| Tall-VS-Normal |
2.27419971743359E-10 |
| Follicular-VS-Other |
2.620800E-01 |
| Follicular-VS-Normal |
8.646800E-04 |
| Other-VS-Normal |
8.299600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.70309999997431E-07 |
| Normal-vs-N1 |
2.76440004221001E-09 |
| N0-vs-N1 |
2.175500E-02 |
|
|
